CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 30, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, announced today that the company’s lead product candidate, ALN-RSV01, was found to be safe and well tolerated when administered intranasally in two Phase I clinical studies. ALN-RSV01 is being evaluated for the treatment of respiratory syncytial virus (RSV) infection and is the first RNAi therapeutic in human clinical development for an infectious disease.
